Thursday, January 29, 2026 1/29/2026

SARS-CoV-2 correlates of protection in a Latino-origin population

Award Number: U01CA260541
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

SARS-CoV-2 correlates of protection in a Latino-origin population - SUMMARY/ABSTRACT Although more than four years have passed since the initial virus appearance, nowadays, most of the population has been vaccinated with multiple doses of mRNA-based vaccines and has endured multiple infection events. Still, SARS-CoV-2 continues to cause disproportionately higher morbidity and mortality in older adults from these communities, especially in the Latino-origin population and other vulnerable populations like the hematopoietic stem cell transplants (HSCT) population. As newer versions of vaccines are adapted to recent SARS-CoV-2 variants (i.e., bivalent vaccines andXBB1.5), we must continue to determine how effective these vaccines are overtime against emerging variants and establish how those populations are still responding. We will characterizes the kinetics, magnitude, and durability of type-specific neutralizing antibody and T cells responses to different current SARS-CoV-2 variants after natural infection or vaccination, designed to reveal correlates associated with protective immunity or disease severity or progression to long COVID. We pursue to implement the following new tasks: AIM 1: Task 1.3. Implementation of a third Community Assessment for Public Health Emergency Response (CASPER) approach, we expect to collect about 2,000 new samples to expand the IDRB. During prior funding periods, we also supported CASPER I and II. AIM 2: Task 2.5: To evaluate the current anti-SARS-Cov-2 IgG levels in the population of Puerto Rico following the Community Assessment for Public Health Emergency Response (CASPER) approach. Task 2.6: characterizes the kinetics, magnitude, and durability of type-specific neutralizing antibody responses to different current SARS-CoV-2 variants designed to reveal correlates associated with protective immunity. Task 2.7: Supported in our prior findings, we propose determining whether such IgG4 levels induced by mRNA vaccination could be associated with persistent COVID-19 symptoms (Long-COVID) in our population. Task 2.8: Interrogation of the Antigen-Specific B Cell Response as described below in the approach section. Task 2.9: Breakthrough SARS-CoV-2 Infections: Investigate the relationship between breakthrough infections, vaccine immunogenicity, and long COVID symptomatology by actively monitoring HSCT patients. AIM3: Task 3.2: Expand the Innate and Adaptive Immune Response characterization in underrepresented populations: Investigate the phenotype and function of antigen-specific T cells, including TFH cells, which support antigen-specific B cell responses. Measure CD4 TFH cells' ability to support antigen-specific B cell antibody secretion using in vitro CD4-B cell cultures. Task 3.3: Define factors responsible for decreased T cell help leading to altered antigen-specific antibody responses in patients with HSCTs. AIM 4: Task 4.3: We will continue to focus on sequencing the circulating and emerging strains and variants and correlating them with the immunological profile characterized under the new tasks in aims 1 to 3. We will continue with our efforts directed to guarantee a proper representation of age, sex, gender, and socioeconomic status as well as individuals with comorbidities including but not limited to obesity, cancer, and autoimmune diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$36,861 )
2026	2024	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	000	2	1/2/2026	SUPPLEMENT FOR EXPANSION	-$36,861
														Subtotal = -$36,861

Issue Date FY: 2025 ( Subtotal = -$511,271 )
2025	2020	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	000	1	2/4/2025	NEW	-$511,271
														Subtotal = -$511,271

Issue Date FY: 2024 ( Subtotal = $812,000 )
2024	2024	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	002	2	8/16/2024	SUPPLEMENT FOR EXPANSION	$812,000
2024	2022	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	000	2	8/16/2024	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2022	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	001	2	8/16/2024	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $812,000

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	001	2	6/21/2023	EXTENSION WITH OR WITHOUT FUNDS	$0
2023	2022	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	B622 MAIN BUILDING FLR 6	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	000	2	3/24/2023	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $1,217,487 )
2022	2022	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	MAIN BLDG FLR 6 B-622	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	001	2	9/16/2022	EXTENSION WITH OR WITHOUT FUNDS	$810,388
2022	2022	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	MAIN BLDG FLR 6 B-622	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	002	2	9/21/2022	SUPPLEMENT FOR EXPANSION	$407,099
2022	2020	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	MAIN BLDG FLR 6 B-622	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	000	1	2/14/2022	NEW	$0
														Subtotal = $1,217,487

Issue Date FY: 2020 ( Subtotal = $1,413,439 )
2020	2020	UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS	MAIN BLDG FLR 6 B-622	SAN JUAN	PR	00935	SAN JUAN	USA	Cancer Detection and Diagnosis Research	000	1	9/23/2020	NEW	$1,413,439
														Subtotal = $1,413,439

Grand Total All Awards = $2,894,794

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SARS-CoV-2 correlates of protection in a Latino-origin population

Award Number: U01CA260541

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer